ArticleCancer chemotherapy and pharmacology2012

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Qian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.